Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 20/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 11/20 | 0.60 |
| ▸ | CTSD | P07339 | 4/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2076550 | 0.95 | BACE1 (0.60) | BACE1CYP3A4CTSD | |
| SCHEMBL3573065 | 0.91 | BACE1 (0.66) | BACE1CYP3A4CTSD | |
| SCHEMBL3573069 | 0.91 | BACE1 (0.66) | BACE1CYP3A4CTSD | |
| SCHEMBL4344083 | 0.91 | BACE1 (0.68) | BACE1CYP3A4CTSD | |
| SCHEMBL4342758 | 0.91 | BACE1 (0.56) | BACE1CYP3A4CTSD | |
| SCHEMBL2076783 | 0.87 | BACE1 (0.66) | BACE1CYP3A4CTSD | |
| SCHEMBL2079576 | 0.87 | BACE1 (0.55) | BACE1CYP3A4CTSD | |
| SCHEMBL3574956 | 0.85 | BACE1 (0.68) | BACE1CYP3A4CTSD | |
| SCHEMBL2078325 | 0.85 | BACE1 (0.64) | BACE1CYP3A4CTSD | |
| SCHEMBL2078327 | 0.85 | BACE1 (0.64) | BACE1CYP3A4CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8552181-B2 | Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2013-10-08 | — | — | US | claimed |
| US-20120220583-A1 | SUBSTITUTED HYDROXYETHYL AMINE COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2012-08-30 | — | — | US | claimed |
| US-20090275602-A1 | Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2009-11-05 | — | — | US | claimed |
| US-20070185144-A1 | Beta-secretase modulators and methods of use | AMGEN INC. (US) | 2007-08-09 | — | — | US | claimed |
| US-8552181-B2 | Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2013-10-08 | — | — | US | disclosed |
| US-20120220583-A1 | SUBSTITUTED HYDROXYETHYL AMINE COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2012-08-30 | — | — | US | disclosed |
| US-20090275602-A1 | Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2009-11-05 | — | — | US | disclosed |
| WO-2008147547-A1 | SUBSTITUTED HYDROXYETHYL AMINE COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2008-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275602-A1 | Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use | BACE1, BACE2, APP | BACE1 1/4885CYP3A4 806/4885CTSD 615/4885 |
| US-20120220583-A1 | SUBSTITUTED HYDROXYETHYL AMINE COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | BACE1, BACE2, APP | BACE1 1/4885CYP3A4 1411/4885CTSD 368/4885 |
| US-20070185144-A1 | Beta-secretase modulators and methods of use | BACE1, BACE2, APP | BACE1 1/4885CYP3A4 2514/4885CTSD 166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.